PeerView Oncology


Exploring Antibody Therapy in ALL: How and Why to Integrate Antibody-Based Treatment Into Patient Management

presented by PeerView Oncology

3 others would like to attend.

I need an invite

Notification icon Friday, December 4, 2020 8 AM - 9:30 AM America/Los_Angeles

Event info

Click HERE to register.

Join Professor David I. Marks, MB, MS, FRACP, PhD, FRCPath, Daniel J. DeAngelo, MD, PhD, and Nicholas J. Short, MD, in PeerView’s “Tumor Board” symposium preceding the virtual 62nd ASH Annual Meeting and Exposition. Leading hematology-oncology experts will discuss the most recent clinical evidence supporting modern antibody options in ALL, explore their increasing therapeutic applications, and gauge the progress in improving patient outcomes across a range of ALL populations and treatment settings. Register today for this important educational event!

Activity Description

Innovations in the management of acute lymphoblastic leukemia (ALL) have included the optimization of multi-agent chemotherapy regimens through the use of asparaginase compounds, the validation of tyrosine kinase inhibitors in certain disease settings, and, more recently, the emergence of antibody–drug conjugates, bispecific antibodies, and adoptive cell therapy agents. Looked at more closely, the development of antibody therapy in ALL and its integration into care can be considered a model for how to enhance standard treatment protocols over a range of settings, including induction/consolidation strategies prior to transplant, and as a way to induce deep, minimal residual disease–negative responses.

Target Audience

This activity has been designed to meet the educational needs of physician specialists in hematology-oncology and other care team professionals engaged in the management of patients with ALL.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Discuss current practice guidelines illustrating the role of antibody therapy in the management of newly diagnosed or relapsed/refractory ALL, including in Ph-negative or -positive disease, as a pretransplant strategy, or in patients with residual disease
  • Cite current evidence surrounding innovative antibody-based approaches, including antibody–drug conjugates and bispecific antibodies, in the management of ALL
  • Select evidence-based regimens with antibody components for the management of patients with ALL
  • Manage safety considerations related to the use of antibody therapy in patients with Ph-negative or -positive ALL


Chair & Presenter

Professor David I. Marks, MB, MS, FRACP, PhD, FRCPath
University Bristol NHS Foundation Trust
Bristol, United Kingdom


Daniel J. DeAngelo, MD, PhD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Nicholas J. Short, MD
The University of Texas
MD Anderson Cancer Center
Houston, Texas


The Medical Learning Institute, Inc. designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit™.

3 others would like to attend.

I need an invite

Login to view comments. Click here to Login